Our advanced Antisense Oligonucleotides (ASOs) design technologys offer a versatile approach for precisely manipulating gene expression, including the potent capability of exon skipping to modulate protein production, such as Ig genes or BCR, by targeting donor splice sites. This method is compatible with both cell lines and primary cells, offering flexibility and applicability across various experimental systems. Whether investigating disease mechanisms, validating therapeutic targets, or developing novel treatments, ASOs provide a powerful tool for advancing biomedical research and clinical translation.
Innover, collaborer, transformer la recherche en solutions
